DANVERS, Mass. Abiomed, a leading provider of breakthrough heart support technologies, announced today that it has submitted U.S Food & Drug Administration (FDA) pre-market approval (PMA) supplemental ...
DANVERS, Mass.--(BUSINESS WIRE)--The United States Food and Drug Administration (FDA) has issued an emergency use authorization (EUA) for Impella RP to include patients suffering from COVID-19 related ...
Use of a microaxial flow pump (Impella CP) with standard care led to a lower risk for death than standard care alone in patients with ST-elevation myocardial infarction (STEMI)-related cardiogenic ...
BOSTON--(BUSINESS WIRE)--Results of a new per-protocol analysis of the ST-segment Elevation Myocardial Infarction Door-To-Unload (STEMI DTU) pilot trial data show significantly reduced infarct size in ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Please provide your email address to receive an email when new articles are posted on . Risk for death was lower with the pump vs. standard care only, but incidence of adverse events was elevated. The ...
As an example of how this technology might be used in future clinical practice, Abiomed has already trained an AI algorithm to predict the next five minutes of a patient’s arterial pressure based only ...
DANVERS, Mass., April 8, 2024 – A late breaking clinical trial, presented at the American College of Cardiology conference and simultaneously published in the New England Journal of Medicine, confirms ...
At Abiomed's European headquarters in Aachen, Germany, Impella heart pumps have been developed and produced for more than 20 years to stabilize and recover the human heart. The single access procedure ...
SALT LAKE CITY, March 11, 2025 /PRNewswire/ — In a transformative recent study, the Second Heart Assist Inc. Whisper™ device, a next-generation percutaneous mechanical circulatory support (pMCS) ...
ATLANTA -- Routine use of the Impella CP microaxial flow pump significantly improved survival in patients with infarct-related cardiogenic shock, the randomized DanGer Shock trial showed. In more than ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results